

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON
JUNE 27, 2023**

The Board announces that at the AGM held on June 27, 2023, all proposed resolutions as set out in the notice of the AGM were duly passed by the shareholders of the Company by way of poll.

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi Biologics (Cayman) Inc. 藥明生物技術有限公司* (the “**Company**”) announces that at the annual general meeting of the Company (the “**AGM**”) held on June 27, 2023, all proposed resolutions as set out in the notice of the AGM were duly passed by the shareholders of the Company by way of poll. Unless otherwise defined, terms used herein shall have the same meanings as those defined in the circular dated May 23, 2023 (the “**Circular**”). The executive Directors, Dr. Zhisheng Chen and Dr. Weichang Zhou; and the independent non-executive Directors, Mr. William Robert Keller and Mr. Jackson Peter Tai attended the AGM either in person or by electronic means.

The poll results taken at the AGM were as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and of the independent auditor of the Company for the year ended December 31, 2022.	2,807,885,762 (99.86%)	3,869,500 (0.14%)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
2.	(a) To re-elect Dr. Ge Li as non-executive Director.	2,035,546,166 (72.40%)	775,884,096 (27.60%)
	(b) To re-elect Dr. Zhisheng Chen as executive Director.	2,683,673,955 (95.44%)	128,081,307 (4.56%)
	(c) To re-elect Mr. Kenneth Walton Hitchner III as independent non-executive Director.	1,421,105,904 (50.55%)	1,390,324,358 (49.45%)
	(d) To re-elect Mr. Jackson Peter Tai as independent non-executive Director.	2,768,721,671 (98.42%)	44,590,591 (1.58%)
3.	To authorize the Board or any duly authorized board committee to fix the Directors' remuneration for the year ending December 31, 2023.	2,724,404,942 (96.89%)	87,350,320 (3.11%)
4.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors and to authorize the Board or any duly authorized board committee to fix their remuneration.	2,765,429,557 (98.35%)	46,325,705 (1.65%)
5.	(a) To approve and adopt the Proposed Amendments to the Scheme (as defined in the notice convening the AGM), and to authorize the Directors to do all things necessary or expedient to implement the amended and restated Restricted Share Award Scheme of the Company which incorporates the Proposed Amendments to the Scheme.	2,079,103,408 (73.94%)	732,651,854 (26.06%)

Ordinary Resolutions		Number of Votes (Approximate%)	
		For	Against
	(b) To approve and adopt the Proposed Amendments to the Program (as defined in the notice convening the AGM), and to authorize the Directors to do all things necessary or expedient to implement the amended and restated Share Award Scheme for Global Partner Program of the Company which incorporates the Proposed Amendments to the Program.	2,077,827,957 (73.90%)	733,927,305 (26.10%)
6.	To approve the adoption of Scheme Mandate Limit (as defined in the notice convening the AGM).	2,188,243,352 (77.82%)	623,511,910 (22.18%)
7.	To grant a general mandate to the Directors to issue, allot and deal with the shares of the Company.	1,910,138,762 (67.93%)	901,616,500 (32.07%)
8.	To grant a general mandate to the directors to repurchase the shares of the Company.	2,808,571,262 (99.89%)	3,184,000 (0.11%)
Special Resolution		For	Against
9.	To approve the adoption of third amended and restated memorandum and articles of association of the Company, which contain the proposed amendments to the Existing Memorandum and Articles of Association (as defined in the notice convening the AGM) as set out in Appendix IV of the circular of the Company dated May 23, 2023, in substitution for, and to the exclusion of, the Existing Memorandum and Articles of Association.	2,811,725,762 (99.99%)	29,500 (0.01%)

As at the date of the AGM, the total number of shares of the Company in issue was 4,248,411,768 Shares, being the total number of Shares entitling the holders thereof to attend and vote on all the resolutions proposed at the AGM.

There were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the AGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company's Hong Kong branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
WuXi Biologics (Cayman) Inc.

Dr. Ge Li

Chairman

Hong Kong, June 27, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III and Mr. Jackson Peter Tai as independent non-executive Directors.

* *For identification purpose only*